entertainment -WSS

entertainment

author：knowledge 2025-09-28 00:52:27 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Amid AI frenzy, a top HHS official's quest to create safeguards

WSS

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

How many hemophilia patients actually want gene therapy?

Why scientists need input from humanists on sensitive research

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

John Green on his newest strategy for fighting tuberculosis

As AI in medicine takes off, can 'human in the loop' prevent harm?

knowledge

entertainment

hotspot

Heart attack and stroke risk calculators need revising

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Supreme Court strikes down use of affirmative action

UCLA team creates talking throat patch for voice disorders

Guidelines to prevent youth baseball injuries need more muscle

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

leisure time

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Climate activists disrupt London Pride march to protest corporate sponsorship

Rock icon Freddie Mercury pre

How many hemophilia patients actually want gene therapy?

UCLA team creates talking throat patch for voice disorders

hotspot

leisure time

focus

leisure time